UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/586,675	07/20/2006	Ekkehard Mueh	288839US0PCT	8067	
22850 7590 06/24/2011 OBLON, SPIVAK, MCCLELLAND MAIER & NEUSTADT, L.L.P. 1940 DUKE STREET			EXAMINER		
			MILLER, JR, JOSEPH ALBERT		
ALEXANDRIA, VA 22314			ART UNIT	PAPER NUMBER	
			1715		
		NOTIFICATION DATE	DELIVERY MODE		
			06/24/2011	ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@oblon.com oblonpat@oblon.com jgardner@oblon.com

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/586,675	MUEH ET AL.		
Exami ne r	Art Unit		
JOSEPH MILLER, JR	1715		

	JOSEPH WILLEN, JA	1713					
The MAILING DATE of this communication appe	ars on the cover sheet with the c	correspondence add	ress				
THE REPLY FILED <u>14 June 2011</u> FAILS TO PLACE THIS APP	LICATION IN CONDITION FOR A	LLOWANCE.					
1. The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following rapplication in condition for allowance; (2) a Notice of Appelor Continued Examination (RCE) in compliance with 37 Coperiods:	the same day as filing a Notice of a ceplies: (1) an amendment, affidavinal (with appeal fee) in compliance	Appeal. To avoid abar t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request				
a) The period for reply expiresmonths from the mailing	date of the final rejection.						
b) The period for reply expires on: (1) the mailing date of this Arno event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (l	ter than SIX MONTHS from the mailing	g date of the final rejection	on.				
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).						
Extensions of time may be obtained under 37 CFR 1.136(a). The date of have been filed is the date for purposes of determining the period of extrunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	ension and the corresponding amount of the corresponding a	of the fee. The appropria nally set in the final Offic	ate extension fee e action; or (2) as				
2. The Notice of Appeal was filed on A brief in comp	liance with 37 CFR 41.37 must be	filed within two month:	s of the date of				
filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed wi	sion thereof (37 CFR 41.37(e)), to	avoid dismissal of the					
AMENDMENTS							
3. The proposed amendment(s) filed after a final rejection, be (a) They raise new issues that would require further core	sideration and/or search (see NO		cause				
(b) They raise the issue of new matter (see NOTE below	•	dualna ar almonlifuina t	na laguag for				
(c) They are not deemed to place the application in bett appeal; and/or			ne issues for				
(d) They present additional claims without canceling a c	, -	ected claims.					
NOTE: <u>See Continuation Sheet</u> . (See 37 CFR 1.1			DTOL 004)				
4. The amendments are not in compliance with 37 CFR 1.12		mpilant Amendment (PTOL-324).				
5. Applicant's reply has overcome the following rejection(s):							
6. Newly proposed or amended claim(s) would be all non-allowable claim(s).	·	•					
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is proved the status of the claim(s) is (or will be) as follows: Claim(s) allowed:		i be entered and an e.	xplanation of				
Claim(s) objected to: Claim(s) rejected: <i>1-3 and 6-8.</i>							
Claim(s) rejected: <u>1-5 and 5-5</u> . Claim(s) withdrawn from consideration: <u>4 and 5</u> .							
AFFIDAVIT OR OTHER EVIDENCE							
8. The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).							
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to or showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea	al and/or appellant fail:	s to provide a				
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after er	ntry is below or attach	ed.				
11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.							
12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s).							
13. Other:							
/Timothy H Meeks/	/JOSEPH MILLER JR/						
Supervisory Patent Examiner, Art Unit 1715	Examiner, Art Unit 1715						

Continuation of 3. NOTE: The previously filed claims were not limited to the precursor species and precursors named and therefore the case would require further searching based upon revised claim.

Continuation of 11. does NOT place the application in condition for allowance because: The further limiting of claimed species appears to overcome the appllied prior art, in the manner applied. Due to the breadth of the claims, not all possible precursors (i.e. as per claim 3) or all groups of precursors (as per claim 1) were previously searched. The further limiting of the claims requires a new search for the more now limited compounds. It is further noted that though certain species were cancelled, the prior art of record could be relied upon for obviousness arguments in combination with other prior art disclosing the claimed compounds, in view of the expected usefulness of homologous or analgous compounds (see MPEP 2144.09).